Experienced in Memory Loss

Dr. Meenakshi C. Patel

Geriatrics | Internal Medicine
6611 Clyo Rd, Suite E, 
Centerville, OH 
 (862.7 mi)
Accepting New Patients
Experienced in Memory Loss
6611 Clyo Rd, Suite E, 
Centerville, OH 
 (862.7 mi)
OverviewInsuranceLocationsClinical Research

Overview

Meenakshi Patel is a Geriatrics specialist and an Internal Medicine provider in Centerville, Ohio. Dr. Patel and is rated as an Experienced provider by MediFind in the treatment of Memory Loss. Her top areas of expertise are Alzheimer's Disease, Hypertensive Heart Disease, Enlarged Liver, and Pediatric Myocarditis. Dr. Patel is currently accepting new patients.

Her clinical research consists of co-authoring 7 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Geriatrics
Internal Medicine
Licenses
Geriatric Medicine in OH
Hospital Affiliations
Miami Valley Hospital
Kettering Health Main Campus
Kettering Health Dayton
Languages Spoken
English
Hindi
Marathi
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Medical Health
  •  CareSource
  •  UnitedHealthcare
  •  Humana

Locations

VALLEY MEDICAL PRIMARY CARE, INC
6611 Clyo Rd, Suite E, Centerville, OH 45459

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
Enrollment Status: Completed
Publish Date: October 08, 2024
Intervention Type: Biological
Study Drug: RSVPreF3
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology
A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology
Enrollment Status: Completed
Publish Date: September 07, 2020
Intervention Type: Drug, Procedure
Study Phase: Phase 3
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 7 Less Clinical Trials

7 Total Publications

INSULIN GLARGINE 300 U/ML IS ASSOCIATED WITH LESS WEIGHT GAIN WHILE MAINTAINING GLYCEMIC CONTROL AND LOW RISK OF HYPOGLYCEMIA COMPARED WITH INSULIN GLARGINE 100 U/ML IN AN AGING POPULATION WITH TYPE 2 DIABETES.
INSULIN GLARGINE 300 U/ML IS ASSOCIATED WITH LESS WEIGHT GAIN WHILE MAINTAINING GLYCEMIC CONTROL AND LOW RISK OF HYPOGLYCEMIA COMPARED WITH INSULIN GLARGINE 100 U/ML IN AN AGING POPULATION WITH TYPE 2 DIABETES.
Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Published: November 07, 2017
Similar Doctors
Distinguished in Memory Loss
Dr. Jason P. Graff
Geriatrics | Internal Medicine
Distinguished in Memory Loss
Dr. Jason P. Graff
Geriatrics | Internal Medicine

The Christ Hospital Medical Associates, LLC

4900 Babson Pl, Suite 400, 
Cincinnati, OH 
 (36.8 mi)
513-564-3870
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jason Graff is a Geriatrics specialist and an Internal Medicine provider in Cincinnati, Ohio. Dr. Graff and is rated as an Advanced provider by MediFind in the treatment of Memory Loss. His top areas of expertise are Memory Loss, Alzheimer's Disease, Cerebellar Degeneration, and Neuronal Intranuclear Inclusion Disease (NIID). Dr. Graff is currently accepting new patients.

Distinguished in Memory Loss
Dr. Robert S. Keyes
Geriatrics | Internal Medicine
Distinguished in Memory Loss
Dr. Robert S. Keyes
Geriatrics | Internal Medicine

Powerback Rehabilitation LLC

9255 Us Hwy 42, 
Union, KY 
 (55.9 mi)
859-305-5173
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Keyes is a Geriatrics specialist and an Internal Medicine provider in Union, Kentucky. Dr. Keyes and is rated as an Advanced provider by MediFind in the treatment of Memory Loss. His top areas of expertise are Alzheimer's Disease, Cerebellar Degeneration, Memory Loss, and Lewy Body Dementia (LBD). Dr. Keyes is currently accepting new patients.

Advanced in Memory Loss
Dr. Dana H. Andrews
Geriatrics | Internal Medicine
Advanced in Memory Loss
Dr. Dana H. Andrews
Geriatrics | Internal Medicine
5900 Parkwood Place Ste 100, 
Dublin, OH 
 (60.7 mi)
614-794-4500
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Dana Andrews is a Geriatrics specialist and an Internal Medicine provider in Dublin, Ohio. Dr. Andrews and is rated as an Advanced provider by MediFind in the treatment of Memory Loss. His top areas of expertise are Memory Loss, Epilepsy, Landau-Kleffner Syndrome, and Cerebral Palsy. Dr. Andrews is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile